Tiludronic Acid

CHEMBL1350 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

318.6 g/mol

LogP

-0.3

Phase

4

Tiludronic acid is a second-generation bisphosphonate that inhibits osteoclast-mediated bone resorption by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, reducing geranylgeranylation of small GTPase signaling proteins essential for osteoclast function. It is approved for the treatment of Paget's disease of bone (osteitis deformans) to reduce elevated bone turnover, decrease bone pain, and normalize alkaline phosphatase levels. Its bisphosphonate mechanism provides durable suppression of osteoclast activity through direct binding to hydroxyapatite.

Peso molecular

318,6100 g/mol

LogP

-0,30

TPSA

140,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Osteoporosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=P(O)(O)C(Sc1ccc(Cl)cc1)P(=O)(O)O

InChI

InChI=1S/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)

Molecular Formula

C7H9ClO6P2S

HBD / HBA

4 / 7

Enlaces Rotables

4

Átomos Pesados

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Tiludronic acid is a second-generation bisphosphonate that inhibits osteoclast-mediated bone resorption by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, reducing geranylgeranylation of small GTPase signaling proteins essential for osteoclast function. It is approved for the treatment of Paget's disease of bone (osteitis deformans) to reduce elevated bone turnover, decrease bone pain, and normalize alkaline phosphatase levels. Its bisphosphonate mechanism provides durable suppression of osteoclast activity through direct binding to hydroxyapatite.

Yes, Tiludronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1350. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 60937. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Tiludronic Acid en PillFYI

Estructura

Datos Rápidos

Fórmula: C7H9ClO6P2S

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.